Avelumab (MSB0010718C; anti-PD-L1) in combination with other cancer immunotherapies in patients with advanced malignancies: The phase 1b/2 JAVELIN Medley study. Background: MGD009 is a B7-H3 x CD3 ...
Charge heterogeneity in monoclonal antibodies can negatively impact binding affinity and potency, so it is critical to ensure that individual charge variants of biotherapeutic molecules are thoroughly ...
Surface plasmon resonance (SPR) technology is expanding strategies for studying and analyzing binding kinetics, offering real-time, label-free analysis. Researchers at the “Developments in Protein ...
Fragment-based drug discovery (FBDD) has gained widespread recognition as a valuable approach in the search for lead drug candidates in drug discovery programs. It is utilized in conjunction with ...